Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.
News|Articles|December 15, 2025
Nonhormonal Therapies Transform Hot Flash Treatment in Menopause
Author(s)Celeste Krewson
Fact checked by: Patrick Campbell
Menopause care transforms with FDA-approved nonhormonal treatments, offering effective relief from hot flashes and improving quality of life for women.
Advertisement
Advertisement
In 2025, major shifts to the landscape of non-hormonal therapies available for treating vasomotor symptoms (VMS) in postmenopausal women were reported, the most recent being the FDA approval of elinzanetant (Lynkuet) in this population on October 24, 2025.1
Related to this article
Smoking was associated with greater odds of EPI, and prevalence ranged from 21.1% to 52.1% depending on the diagnostic test used.
Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.
Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.
Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.
Ochsner Transplant Institute director discusses liver transplant care, robotic kidney transplant, organ preservation, and access gaps.
Mirum's antibody led to virologic response and ALT normalization in up to 56% of patients at week 24, vs 0% with delayed treatment.
Murad Alam, MD, and Elizabeth Kiracofe, MD, discuss how reimbursement, coverage, and advocacy shape dermatology access for patients with skin of color.
Advertisement
Advertisement